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CD1-restricted lipid-specific T lymphocytes are
primed during infection with Mycobacterium tuber-
culosis, the causative agent of tuberculosis. Here
we describe the antigenicity of glycerol monomyco-
late (GroMM), which stimulates CD1b-restricted
CD4+ T cell clones. Chemical characterization of
this antigen showed that it exists as two stereoiso-
mers, one synthetic isomer being more stimulatory
than the other. The hydroxyl groups of glycerol and
the mycolic acid length are critical for triggering the
T cell responses. GroMMwas presented byM. tuber-
culosis-infected dendritic cells, demonstrating that
the antigen is available for presentation during natural
infection. Ex vivo experiments showed that GroMM
stimulated T cells from vaccinated or latently infected
healthy donors but not cells from patients with active
tuberculosis, suggesting that GroMM-specific T cells
are primed during infection and their detection corre-
lates with lack of clinical active disease.
INTRODUCTION
T lymphocytes participate in host defense against microbial
pathogens, includingMycobacterium tuberculosis, the causative
agent of tuberculosis. During M. tuberculosis infection, both
conventional and unconventional T cells are stimulated. Conven-
tional T cells use an ab T cell receptor (TCR) and recognize
peptide antigens presented by major histocompatibility complex
(MHC) II or MHC I antigen-presenting molecules on antigen-
presenting cells (APCs), whereas unconventional T cells include
gd TCR cells specific for mycobacterial phosphorylated ligands
and CD1-restricted ab TCR cells recognizing mycobacterial lipid
antigens (De Libero and Mori, 2005; Moody et al., 2005; Skold
and Behar, 2005). Five CD1 proteins (CD1a, b, c, d, and e) are ex-
pressed by human cells. CD1a to CD1d have antigen presenting
functions, whereas CD1e facilitates glycolipidic antigen pro-
cessing (de la Salle et al., 2005).82 Chemistry & Biology 16, 82–92, January 30, 2009 ª2009 ElsevieCD1-restricted T cells are activated in the course of M. tuber-
culosis infections (Gilleron et al., 2004; Moody et al., 2000b;
Ulrichs et al., 2003). Although in vivo data in animal models are
only preliminary (Dascher et al., 2003; Hiromatsu et al., 2002),
CD1-restricted T cells have been indicated to contribute to
protection during infection because they kill intracellular patho-
gens and secrete proinflammatory cytokines, which in turn
promote macrophage bactericidal activity (Gilleron et al.,
2004). These studies have highlighted lipids of the mycobacterial
envelope as key determinants of host immune response. Thus,
mycobacterial lipids are now considered to be a novel class of
antigens that could be used in subunit vaccine formulations.
There is much evidence in support of this: (i) lipid antigens prime
specific T cells during infection (Gilleron et al., 2004; Moody
et al., 2000b; Ulrichs et al., 2003); (ii) because lipids are products
of multistep biosynthetic pathways, in contrast to microbial
protein antigens, their selection-induced structural variation is
difficult; and (iii) CD1 proteins are less polymorphic than MHC
proteins and, therefore, stimulatory lipids are probably immuno-
genic in the entire population. Two studies have shown that
M. tuberculosis lipids used to vaccinate guinea pigs improve
the pulmonary pathology (Dascher et al., 2003; Hiromatsu
et al., 2002). These promising initial vaccination experiments
also support the development of novel subunit vaccines priming
immunity against mycobacterial lipid antigens (Martin, 2005;
Skeiky and Sadoff, 2006).
The envelope of M. tuberculosis has an extraordinarily high
lipidic content and a large number of structurally diverse lipids
(Brennan and Nikaido, 1995). Only a few of these molecules
have been shown to stimulate CD1-restricted T cells and the
repertoire of mycobacterial lipid antigens is large. Immunogenic
lipids are mostly presented by CD1b (Moody et al., 2005; Skold
and Behar, 2005) and include molecules with very diverse
structures like free mycolic acids (Beckman et al., 1994),
glucose-6-O-monomycolate (Moody et al., 1997), diacylated
sulfoglycolipids (Gilleron et al., 2004), or mannosyl-phosphati-
dylinositol-based glycolipids such as lipoarabinomannans
(LAM) (Sieling et al., 1995), lipomannans (LM) (Sieling et al.,
1995), and PIM (de la Salle et al., 2005; Ernst et al., 1998). CD1a
presents the lipopeptide dideoxymycobactin (Moody et al.,
2004), whereas CD1c presents mannosyl-phosphomycoketidesr Ltd All rights reserved
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of mycobacterial lipid antigens, we generated a panel of
T cell clones using partially purified lipids (Gilleron et al.,
2004). These T cells were used to identify immunogenic
lipids. We now describe a new lipid antigen, glycerol
monomycolate (GroMM), found among different bacteria of
the Corynebacterium, Mycobacterium, and Nocardia (CMN)
group. GroMM is presented by CD1b in a CD1e-independent
manner, by DCs infected with M. tuberculosis. GroMM-
specific T cells are detected in the circulating blood of puri-
fied protein derivative (PPD)-positive healthy donors but not
in that of patients with active tuberculosis, raising the ques-
tion of their role in the course of this disease.
RESULTS
Characterization of the Z5B71 T Cell Clone
To characterize the repertoire of CD1-restricted M. tuberculosis
lipid antigens, we generated T cell clones using three crude
mycobacterial lipid fractions differing in polarity and charge (Gil-
leron et al., 2004). Here we describe the immunological charac-
teristics and the lipid antigen stimulating the Z5B71 T cell clone
that was isolated after stimulation with a M. bovis bacillus
Calmette-Gue´rin (BCG) lipid fraction enriched in phosphatidyl-
myo-inositol dimannosides (PIM2) (Gilleron et al., 2008). Z5B71
T cells use an ab TCR and are CD4 positive. They reacted to lipid
extracts from all the mycobacterial species tested, including M.
bovis BCG, M. smegmatis, M. gastri, M. marinum, M. fortuitum,
M. xenopi, M. kansasii, and M. tuberculosis H37Ra and H37Rv,
and also to lipids isolated from Corynebacterium glutamicum
and Nocardia asteroides (Figures 1A and 1B). Thus, the stimula-
tory lipid antigen is probably ubiquitous in bacteria of the CMN
group. M. bovis BCG extracts always appeared to be the most
stimulatory, suggesting that the antigen is more abundant in
this species. This finding, together with the fact that the diversity
of glycolipids is lower in M. bovis BCG than in M. tuberculosis,
prompted us to use an M. bovis BCG extract to identify the stim-
ulatory antigen.
When lipids were partitioned by acetone precipitation (see
Figure S1A available online), the acetone-insoluble fraction
showed the strongest activity (Figure S1B). This fraction was
further precipitated with methanol and the methanol-insoluble
fraction was the most stimulatory (Figure S1C). This latter fraction
was then further fractionated on a silica gel column (Figure S1A).
Z5B71 T cells were stimulated with fractions 5 to 9 (Figure 2B),
which appeared to contain a homogenous product (Figure 2A)
when analyzed by thin-layer chromatography (TLC). Hence, the
active fractions were pooled and analyzed by matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS) and nuclear magnetic resonance (NMR).
Chemical Characterization of the Mycobacterial Lipid
Antigen
The positive mode MALDI mass spectrum showed a complex
pattern of peaks corresponding to cationized sodiated molecular
ions [M+Na]+ (Figure 3A). The main peaks were separated by 28
mass units, suggesting differences of two methylenic units
between each molecular species, possibly as a result of hetero-
geneity in fatty acyl chain length. To confirm this hypothesis, the
product was hydrolyzed under alkaline conditions and the fatty
acids were analyzed by GC (data not shown) and MALDI-TOF
MS (Figure 3B). The positive mode MALDI mass spectrum high-
lighted a series of peaks typical of mycolic acids (Laval et al.,
2001). According to the presence of various chemical functions
on the meromycolic chain, mycolates are subdivided into
a-mycolates, methoxymycolates, and ketomycolates (Daffe and
Draper, 1998). M. tuberculosis contains a ratio of a-mycolates/
oxygenated mycolates (i.e., methoxymycolates and ketomyco-
lates) of 1/1, whereas M. bovis BCG contains predominantly ke-
tomycolates (Watanabe et al., 2001). In agreement with these
data, peaks at m/z 1232, 1260, 1274, 1288, and 1302
(Figure 3B) were assigned to [M+Na]+ forms of ketomycolates
(Figure 3C). The mass difference (D74 amu) with respect to the
native product suggested that the latter consisted of one mycolic
acid esterifying a glycerol residue. Consistent with this notion,
MALDI-MS analysis of the peracetylated molecule showed
a displacement of 126 mass units (data not shown), indicating
the presence of three alcohol functions.
The identification of this novel antigen as GroMM was further
supported by 1D 1H NMR analysis (Figures 4E and 4D). The reso-
nances typical of mycolic acids were assigned according to pub-
lished studies (Quemard et al., 1997; Schroeder and Barry, 2001;
Watanabe et al., 2001). Protons d (d 2.31) and e (d 3.53, multi-
plet), which correlated together on the 2D 1H-1H correlated
spectroscopy (COSY) spectrum (data not shown), were
assigned to the protons of the carbons carrying the a chain
and the b-hydroxyl group, respectively (Figure 4A). The protons
j (d 2.41, multiplet) and k (d 0.92, doublet), which were also corre-
lated on the COSY spectrum, were assigned to the -CHCH3-
group in the distal portion of the meromycolic chain. The signal
l (d 0.75, triplet) was assigned to the protons of the terminal
methyl groups of the a- and meromycolic chains. The multiplets
h at d 0.46, d 0.44, and d 0.52, which were correlated on the
COSY spectrum, represented the characteristic signals of the
cyclopropanic function protons. Signals around 5 ppm (g at
d 5.16 and f at d 4.83) corresponded to olefinic protons,
Figure 1. Immunogenicity of Lipidic Frac-
tions from Various Bacterial Species of the
CMN Group
(A and B) IFN-g release was used to quantify T cell
activation and expressed in nanograms per milli-
liter (mean ± SD; n = 3). The data are representative
of three independent experiments.Chemistry & Biology 16, 82–92, January 30, 2009 ª2009 Elsevier Ltd All rights reserved 83
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tained ethylenic groups. Protons a (d 4.11, 4.06 and 3.99), b (d
3.75), and c (d 3.47) (Figure 4D), which correlated on the 2D
1H-1H HOHAHA spectrum (data not shown), were assigned to
glycerol protons (Figure 4A). However, the protons a were
divided into two independent spin systems, a1 (d 4.11 and
3.99) and a2 (d 4.06) (Figure 4D), whose definitive assignment
was achieved by NMR analysis of synthetic GroMM analogs.
A Hemisynthetic GroMM Stimulates Specific T Cells
In order to confirm the antigenicity of GroMM, analogs were
synthesized (Figure S2) using mycolates isolated from M. tuber-
culosisH37Rv (Figure S3B). The chemical synthesis was initiated
with (R)- or (S)-isopropylidene-glycerol, activated by p-toluene-
sulfonyl (Sowden and Fischer, 1942) (Figure S2). The esterifica-
tion of glycerol by mycolic acids was realized by heating (R)- or
(S)-isopropylidene-glycerol in the presence of potassium myco-
lates (Defaye and Lederer, 1956). The isopropylidene-mycoloyl-
glycerol isomers were then deprotected under acidic conditions
to give synthetic s(R)- or s(S)-GroMM. The MALDI mass spectra
of both sGroMM isomers (Figure S3A) were in agreement with
the expected mass distribution of GroMM-bearing M. tubercu-
losis H37Rv mycolic acids (Figure S3B). These synthetic mole-
cules were then analyzed by 1D 1H NMR (Figure 4B and C).
The s(S)-GroMM showed a protons (designed a1) with chemical
shifts at 4.00 and 4.12 ppm (Figure 4C), whereas the s(R)-GroMM
showed a protons (designed a2) resonating at 4.05 ppm (Fig-
ure 4B). We therefore concluded that natural GroMM, which dis-
played a1 and a2 resonances of similar intensity (Figure 4D), is
Figure 3. Positive Mode MALDI-TOF MS Analysis of M. bovis BCG
GroMM (A) and of the Mycolic Acids Obtained after Saponification
of M. bovis BCG GroMM (B)
(A and B) The asterisk corresponds to a contaminant.
(C) Table showing the calculated masses of the sodium adduct ions of the ex-
pected mycolic acids and of the corresponding GroMM.
Figure 2. Fractionation ofM. bovis BCG ‘‘Methanol-Insoluble’’ Lipid
Pool and Immunogenicity of the Isolated Fractions
(A) TLC analysis of eight representative fractions (1, 3, 5, 10, 18, 19, 28, and 34)
obtained by silica gel chromatography of ‘‘methanol-insoluble’’ lipids. The
encircled spot corresponds to the active compound.
(B) The same fractions were tested for stimulation of Z5B71 T cells. IFN-g
release was used to quantify T cell activation and expressed in nanograms
per milliliter (mean ± SD; n = 3). The data are representative of three indepen-
dent experiments.84 Chemistry & Biology 16, 82–92, January 30, 2009 ª2009 Elsevier Ltd All rights reserved
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s(R)- or s(S)-GroMM to stimulate Z5B71 T cells, we found that the
R isomer was more active than the S one, whereas the natural
compound had an intermediate activity (Figure 5A). These data
confirmed the nature and structure of the natural antigen and
showed that one stereoisomer was preferentially recognized
by the TCR of the specific T cell clone.
Structural Requirements of GroMM for T Cell
Stimulation
Free mycolates have been reported to stimulate CD1b-restricted
T cells, indicating that this structure on its own might form stimu-
latory complexes with CD1b (Beckman et al., 1994; Moody et al.,
1997). However, when mycolates and corynomycolates were
tested in our assay, they did not activate Z5B71 T cells (data
not shown), thus revealing the importance of the glyceryl moiety
in TCR recognition. To evaluate the importance of the alcohol
functions, we acetylated the hydroxyl groups of glycerol. Substi-
tution of an acetyl moiety at position c of Gro (Figure 4A) did not
abolish T cell reactivity, whereas substitution of two acetyl moie-
Figure 4. 1H NMR Analysis of GroMM
The structure of M. bovis BCG GroMM is in pre-
sented in (A). Specific GroMM protons signals are
annotated a to k, and are assigned on the structure
of the major forms of M. bovis BCG GroMM, ester-
ified by ketomycolic acids. n1 = 19, 21, or 23; n2
and n4 = 15, 17, or 19; n3 = 12 to 17.
(B and C) 1H NMR analysis of synthetic (R)-1-O-
mycoloyl-glycerol (B) and (S)-1-O-mycoloyl-glyc-
erol (C). R corresponds to mycolic acid.
(D and E) 1H NMR analysis ofM.bovisBCG GroMM.
ties (at positions b and c) abolished it (data
not shown), suggesting that the hydroxyl
group in position b is involved in T cell
recognition of this lipid. GroMM was also
submitted to periodic acid cleavage and
reduction to generate glycol-monomyco-
late. This compound displayed a drasti-
cally reduced ability to stimulate specific
T cells (data not shown), demonstrating
that the position c, absent in this molecule,
is also important for T cell recognition.
We next investigated whether other
natural mycolate derivatives stimulate
Z5B71 T cells. Glucose-6-O-monomyco-
late (GlcMM), one of the first described
CD1b-presented antigens (Moody et al.,
1997), but neither trehalose-6-O-mono-
mycolate (TMM) nor trehalose-6,60-O-
dimycolate (TDM), showed activity com-
parable to that of GroMM (Figure 5B).
The importance of the number and the
structure, in particular the length, of the
acyl chain(s) on the glycerol unit was first
explored by testing the immunogenicity
of different commercial glycerides. Mono-,
di-, and triglycerides bearing palmitic
acids did not stimulate Z5B71 T cells (data not shown). Hemisyn-
thetic GroMMs were then prepared using corynomycolates (i.e.,
C32 mycolic acid derivatives) isolated from C. glutamicum. The
R isomer stimulated T cells very inefficiently, even at high doses,
whereas the S isomer was nonstimulatory (Figure 5A). However,
GlcMM isolated from C. glutamicum (i.e., with corynomycolates)
showed about the same activity as M. phlei GlcMM (i.e., with
a C80 mycolic acid) (Figure 5C). Collectively, these results show
that both the fatty acid chain length and the hydrophilic head influ-
ence the stimulation of Z5B71 T cells.
GroMM Presentation Is Restricted by CD1b
and Is Not CD1e Dependent
When CD1-transfected APCs were used to investigate the re-
stricting molecule, only those expressing CD1b stimulated
Z5B71 T cells (Figure 6A) and the response was inhibited by
anti-CD1b but not by other anti-CD1 monoclonal antibodies
(mAbs) (Figure 6B). Because CD1e can facilitate the presentation
of complex mycobacterial lipids (de la Salle et al., 2005), we also
investigated whether the antigenicity of GroMM is influenced byChemistry & Biology 16, 82–92, January 30, 2009 ª2009 Elsevier Ltd All rights reserved 85
Chemistry & Biology
GroMM Stimulates CD1b-Restricted CD4+ T CellsCD1e. Similar T cell responses were observed using APCs ex-
pressing only CD1b or both CD1b and CD1e (Figure 6C),
showing that CD1e is not required for GroMM presentation.
M. tuberculosis-Infected Dendritic Cells Stimulate
Z5B71 T Cells
An important issue is whether mycobacterial lipid antigens also
form immunogenic complexes with CD1 molecules during infec-
Figure 5. Biological Activities of Hemisynthetic GroMM, M. bovis
BCG Mycolate Derivatives, and C. glutamicum and M. phlei GlcMM
(A–C) In C32 or C80 s(S)- or s(R)- GroMM, C32 corresponds to corynomycolic
acids and C80 to mycolic acids whereas (S) corresponds to (S)-1-O-mycoloyl-
glycerol and (R) to (R)-1-O-mycoloyl-glycerol. IFN-g release was used to quan-
tify activation of the T cell clone Z5B71 and expressed in nanograms per
milliliter (mean ± SD; n = 3). The data are representative of three independent
experiments.86 Chemistry & Biology 16, 82–92, January 30, 2009 ª2009 Elseviertion. This was explored using DCs pulsed with heat-killed
M. tuberculosis or infected with live bacilli. In both cases a strong
response of GroMM-specific T cells was detected (Figures 6D
and 6E), confirming that this lipid is immunogenic when inserted
into the bacterial cell envelope.
GroMM-Specific T Cells Are Not Detected in Patients
with Active Tuberculosis
To assess whether GroMM-specific T cells participate in the
immune response to M. tuberculosis, we recruited patients
with active tuberculosis (n = 11), latently infected (n = 19), BCG
vaccinated (n = 22), and PPD-negative healthy individuals (n =
10). As a correlate of T cell activation, we determined interferon
(IFN)-g release 6 days after stimulation with GroMM. Compared
with naive donors, where GroMM-stimulated IFN-g release did
not exceed medium background (data not shown), significant
responses were only observed in vaccinated or latently infected
individuals. Similar to naive donors, no GroMM reactivity was
observed in peripheral blood mononuclear cells (PBMCs) of
tuberculosis patients (Figure 6F). This lack of reactivity was
specific for GroMM, because patients responded readily to
PPD (data not shown). To further corroborate the specificity of
GroMM induced IFN-g release, we tested the ex vivo reactivity
to a limited set of unrelated mycobacterial lipids: out of five
donors, only three responded to GroMM; one responded to
phosphatidyl-myoinositol-di-mannoside (PIM2), and only two re-
sponded to di-acyl-trehalose (DAT) (Figure S4). These differential
responses are in agreement with the notion that they represent
a recall of antigen specific T cell memory. GroMM-induced
T cell activation was CD1 restricted, because a cocktail of block-
ing antibodies against CD1a, b, and c, (Figure 6G) but not MHC
class I antibodies (data not shown), inhibited IFN-g release. To
define the specific CD1 isotypes restricting ex vivo T cell
responses, we blocked T cell activation using CD1a, CD1b, or
CD1c antibodies. In three donors, IFN-g release was inhibited
by CD1a and CD1b or CD1a alone. Neutralizing antibodies to
CD1c or IgG1 isotype controls had no effect (Figure S5). In
conclusion, these results demonstrate that GroMM triggers
CD1 restricted T cells in mycobacteria-primed individuals, but
this T cell subset is absent or highly reduced in tuberculosis
patients.
DISCUSSION
The mycobacterial envelope contains a large number of diverse
lipid molecules whose immunogenic potential is not completely
understood. In the present study, we characterized a novel lipid
antigen presented by CD1b, GroMM, which belongs to the my-
coloyl-based class of lipids. GroMM is inserted in the outer layer
of the outer membrane and is present in most of the mycobacte-
rial species. The existence of GroMM in M. bovis BCG (Tsumita,
1956) and in some M. tuberculosis strains was reported in the
1950s (Bloch et al., 1957; Noll, 1957; Noll and Jackim, 1958).
However, the esterification position of the mycoloyl residue on
the glycerol primary OH group was only established 30 years
later (Batrakov, 1985).
Using hemisynthetic molecules, we confirmed the immunoge-
nicity of GroMM and investigated the importance of different
structural elements of GroMM. With M. tuberculosis mycolicLtd All rights reserved
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coloyl-glycerol [s(R)-GroMM] diastereoisomer being more stimu-
latory than the (S)-1-O-mycoloyl-glycerol [s(S)-GroMM] one.
Shortening the mycolic acid chain almost abrogated T cell
response, as indicated by the poor activity of the s(R)-GroMM-
containing corynomycolates and the total absence of activity
of the s(S)-GroMM. This finding showing that the mycolic acid
length influences the T cell response is in accordance with
studies performed with GlcMM (Moody et al., 2002). These
seminal investigations showed that GlcMM with long (C80) acyl
chains required internalization into late endosomes for efficient
presentation, whereas GlcMM with short (C32) acyl chains was
rapidly loaded onto CD1b also on the cell surface. In addition,
C80 GlcMM was more active than the C32 GlcMM, probably
due to formation of stable and/or more immunogenic CD1b
complexes when long fatty acid chains are involved. Whether
Figure 6. Functional In Vitro and Ex Vivo Activities of the GroMM-Specific T Cells
CD1b-restricted and CD1e-independent presentation of GroMM using THP-1 transfected cells (A) and mAbs-mediated inhibition of GroMM-induced T cell acti-
vation (B) using a GroMM-containing fraction. In (C), THP-1-CD1b (-) and THP-1-CD1b-CD1e (d) transfected cells were used. Activation of Z5B71 T cells by DCs
pulsed with heat-killed M. tuberculosis (D) or infected with living M. tuberculosis (E). Release of TNF-a (A and B) or IFN-g (C–G) was used to quantify activation of
Z5B71 T cells and expressed in picograms or nanograms per milliliter (mean ± SD; n = 3). The data are representative of three independent experiments. Ex vivo
reactivity to GroMM: PBMCs from naive (n = 10), BCG-vaccinated (n = 22), or latently infected healthy donors (n = 19) and tuberculosis patients (n = 11) were
stimulated with GroMM in the presence of autologous DCs. After 6 days culture, supernatant was collected and IFN-g concentration determined by ELISA
(F). Medium controls (not shown) were similar for the different donor cohorts and on average below 3 pg/ml. In ten PPD-positive, healthy donors, the restriction
was determined by GroMM stimulation in the presence or absence of a cocktail of CD1 type 1 blocking antibodies (G). Black circles show individual donors,
horizontal bars represent the average for each group. One asterisk indicates a confidence interval of >95%; two asterisks indicate a confidence interval of
>99%; and a confidence interval of <95% was considered to be nonsignificant.Chemistry & Biology 16, 82–92, January 30, 2009 ª2009 Elsevier Ltd All rights reserved 87
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forms more immunogenic and/or more stable complexes with
CD1b remains to be investigated.
The finding that both GlcMM and GroMM activate Z5B71
T cells indicates that they share a common epitope. Chemical
degradation showed that it corresponds to the minimal stimula-
tory structure, thus raising the question of how cross-reactivity
between these two lipids occurs. The crystal structure of
CD1b-GlcMM complexes (Batuwangala et al., 2004) shows
that arginine 79 (R79) on the CD1b a1 helix forms a hydrogen
bond with the oxygen of the alcohol function on the C4 of the glu-
cosyl unit (Figure 7A), possibly stabilizing a specific orientation of
the sugar. Superposition of the GroMM and GlcMM structures
shows that the hydroxyl in position c of GroMM might corre-
spond to GlcMM OH-4, whereas the hydroxyl in position b,
possibly positioned like the oxygen atom of the GlcMM glucose
ring, might be available for cognate interaction with the TCR
(Figures 7B and 7C). We also found that the mycolic acid length
was critical when Z5B71 T cells react to GroMM, but not to
GlcMM. The current paradigm is that the length of fatty acyl
chain affects the polar head positioning and its interaction with
the TCR (Batuwangala et al., 2004; McCarthy et al., 2007; Moody
et al., 2000a, 2002). It is tempting to speculate that the exact
positioning of the polar antigen head dictated by the lipid tail is
more critical for GroMM than for GlcMM because the number
of possible interactions with the TCR is more limited with glycerol
than with glucose.
Collectively, these data suggest that mycolic acids may
constitute a scaffold for lipid antigens, which enables their
binding to CD1b and controls the interaction of different polar
heads with TCR. This resembles the scaffold nature of the ce-
ramide and diacylglycerol moieties of other lipid antigens (Kinjo
et al., 2006; Tsuji, 2006) and thus reveals a more general rule,
whereby scaffold molecules that are well suited to CD1 binding
confer immunogenicity on a large number of lipid molecules.
The observation that GroMM, GlcMM, and free mycolic acid
are presented by CD1b molecules is probably facilitated by the
unique presence of intricate and interconnected hydrophobic
pockets in CD1b. Crystallographic data reveal that the meromy-
colate chain of GlcMM fills the A0, T0, and F0 pockets of CD1b,
protrudes out of the F0 pocket, possibly interacting with the
TCR, whereas the a chain occupies the C0 groove (Batuwangala
et al., 2004). Another reason is that CD1b traffics through acidic
compartments where lipid antigens are loaded with pH-
dependent mechanisms, in some cases after processing (de la
Salle et al., 2005). Although we cannot formally exclude that
the GroMM meromycolate chain is partially degraded before
binding to CD1b, it is more probable that it is stimulatory in its
native form. This is supported by the finding that GroMM analogs
with short fatty acid chains are poorly antigenic and that GroMM
is presented in the absence of CD1e, a CD1 molecule that facil-
itates the processing of complex glycolipid antigens (de la Salle
et al., 2005).
GroMM-specific T cells were detected in the peripheral blood
of BCG-immunized or latently infected donors. Activation of
these T cells was abrogated by CD1a and CD1b blocking anti-
bodies, suggesting that in vivo GroMM can be presented by
these CD1 molecules. This raises the question how GroMM fits
into CD1a pockets. It might be possible towing to the unique88 Chemistry & Biology 16, 82–92, January 30, 2009 ª2009 Elsevieropen conformation of the CD1a F0 pocket, in which mycolic
acid might be partially accommodated, with the remaining part
lying outside, as reported for the sulfatide tail in the CD1a crystal
(Zajonc et al., 2003).
An unexpected finding was that patients with active tubercu-
losis did not respond to GroMM, though they react to Ac2SGL
(Gilleron et al., 2004). Several possible reasons might explain
why tuberculosis patients failed to respond to GroMM. One is
that in the patients tested, a general and antigen-nonspecific
immune suppression could have prevented an in vitro response,
a phenomenon that has been described for the initial phase of
acute disease (Hirsch et al., 1996). However, this explanation is
unlikely because in contrast to GroMM, T cell responses to
mycobacterial protein antigens were readily detectable in the
peripheral blood of the same individuals. Alternatively, GroMM-
specific T cells might be sequestered in inflamed tissues, as sug-
gested for Ag85-specific CD8+ T cells (Caccamo et al., 2006). A
third explanation is that GroMM-specific T cells might participate
in protection against disease and limit the growth of the bacilli.
The absence of these T cells could then directly contribute to
the appearance of clinically active disease. The findings that
Figure 7. Structural Models Explaining the Cross-Reactivity
between GlcMM and GroMM
The glycosyl and glyceryl units were both in close contact with R79.
(A) Model of CD1b-GlcMM complex.
(B) Model of CD1b-GroMM complex.
(C) Superimposition of the two structures, with the glyceryl unit well positioned
on part of the glucosyl ring.Ltd All rights reserved
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GroMM Stimulates CD1b-Restricted CD4+ T CellsGroMM-specific T cells recognize mycobacteria-infected cells
and release proinflammatory cytokines are in accordance with
this hypothesis. Future studies will aim at investigating the
potential protective value of GroMM in subunit vaccine formula-
tions against tuberculosis.
SIGNIFICANCE
The role of CD1-restricted lipid-specific T lymphocytes
during Mycobacterium tuberculosis infection is an impor-
tant issue, because these cells might participate in protec-
tion. M. tuberculosis envelope has an extraordinarily high
lipid content with wide molecular diversity. Although myco-
bacterial lipids with different structures stimulate CD1-
restricted T cells, their relative contribution to specific
immunity during infection is unknown.
Here we describe a novel mycobacterial lipid antigen,
glycerol monomycolate (GroMM), which is presented by
CD1b and stimulates CD4+ T cells. The following findings
describe the rules of GroMM immunogenicity and its contri-
bution to anti-M. tuberculosis repertoire in infected patients.
GroMMwas found as two stereoisomers, (S)- and (R)-1-O-
mycoloyl-glycerol, present in similar proportions in bacilli.
Using hemisynthetic analogs, the R synthetic isomer was
more stimulatory than the S isomer. Both the fatty acid and
the hydrophilic head influence stimulation of GroMM-
specific T cells, as long fatty acid and free hydroxyls of glyc-
erol are essential. GroMM-specific T cells also recognize
glucose-monomycolate (GlcMM), but not TMM or TDM. A
model is proposed to explain this cross-reactivity.
GroMM is presented byM. tuberculosis-infected dendritic
cells, thereby confirming its immunogenicity during infec-
tion. Ex vivo studies using peripheral blood of infected
patients showed that GroMM efficiently stimulates T cells
from PPD-positive healthy donors and not cells from
patients with active tuberculosis, or from noninfected
donors, suggesting that GroMM-specific T cells are primed
during infection and are differently represented in donors
with latent and active tuberculosis.
Thus, the overall data suggest that mycolic acids consti-
tute a scaffold for lipid antigens, which supports their
binding to CD1b and facilitates the interaction of different
polar heads with the TCR.
EXPERIMENTAL PROCEDURES
Reagents
(R)-isopropylidene-glycerol and (S)-isopropylidene-glycerol, glyceryl tripalmi-
tate (tripalmitin), 1,2 dipalmitoyl-sn-glycerol [(S)-glycerol 1,2-dipalmitate] and
monopalmitoyl glycerol (1-O-palmityl-rac-glycerol) were purchased from
Sigma (Saint Quentin Fallavier, France).
Bacterial Strain and Culture Conditions
Nocardia asteroides and Corynebacterium glutamicum were grown in suspen-
sion for 2 to 3 days at 32C on Luria Broth and Brain Heart Infusion medium,
respectively. Mycobacteria were grown for 4 to 8 weeks at 37C on Sauton’s
medium as surface biofilm. Cells were harvested, separated from the culture
media, and left in chloroform/methanol (2:1, v/v) at room temperature to kill
bacteria.Chemistry & Biology 16Cell Culture
Human promyelocytic THP-1 cells were transfected with cDNA of human
CD1A, or CD1B, or CD1C genes, or double-transfected with CD1B and
CD1E using the BCMGS-Neo and -Hygro vectors by electroporation. Cells
were grown in RPMI-1640 supplemented with 10% fetal calf serum (FCS),
10 mM HEPES, 2 mM UltraGlutamine II, MEM nonessential amino acids,
1 mM Na-pyruvate, and 100 mg/ml kanamycin (all from Invitrogen, Basel,
Switzerland). DCs were isolated from PBMCs of healthy donors by culturing
in the presence of recombinant IL-4 and GM-CSF, as described (Porcelli
et al., 1992). T cell clones were generated as described previously (De Libero,
1997), and grown in RPMI-1640 supplemented with 5% AB human serum
(Swiss Red Cross), 10 mM HEPES, 2 mM UltraGlutamine II, MEM nonessential
amino acids, 1 mM Na-pyruvate, 100 mg/ml kanamycin, and 100 U/ml human
recombinant IL-2.
T Cell Activation Assays
DCs (3 3 104/well) or CD1-transfected THP-1 cells (3 3 104/well) were incu-
bated for 2 hr at 37C with different concentrations of sonicated antigens
before addition of T cells (105/well in triplicate). Supernatants were harvested
after 36 hr of incubation, and cytokine release was measured by using
enzyme-linked immunosorbent assay (ELISA) kits (IFN-g from Instrumentation
Laboratory, Schlieren, Switzerland; TNF-a from BD PharMingen, Basel,
Switzerland). Data are expressed as mean pg/ml or ng/ml ± standard deviation
(SD) of triplicates.
Analysis of CD1 Restriction
CD1 restriction was investigated by evaluating the inhibition of T cell response
in the presence of the following mAb at 10 mg/ml added 30 min before T cells:
OKT6 (anti-CD1a, American Type Culture Collection ATCC CRL-8019), WM-
25 (anti-CD1b; Immunokontakt, Lugano, Switzerland), L161 (anti-CD1c;
Instrumentation Laboratory), W6-32 (anti-MHC class I, ATCC) and L243
(anti-MHC class II, ATCC). Anti-TCRVg9 (B3) mAb was used as irrelevant mAb.
Pulsing and Infection of DCs with M. tuberculosis
M. tuberculosis was killed at 80C for 20 min and incubated in RPMI-1640
medium containing 10% FCS for 2 hr at 37C with DCs (3 3 104/well) before
addition of T cells (105/well in triplicate). In other experiments, DCs were in-
fected as previously described (De Libero et al., 2005) and IFN-g release
was monitored by ELISA.
Lipidic Fractions Used for Generation of T Cell Clones
The TCRab CD4+ T cell clone Z5B71 was generated as described (Gilleron
et al., 2004) by stimulating PBMCs of a PPD+ healthy donor with a M. bovis
BCG PIM2-enriched fraction (Gilleron et al., 2001). Briefly, M. bovis BCG cells
were suspended in chloroform/methanol (1:1, v/v) and filtered four times. The
chloroform/methanol extract was concentrated and constituted the lipidic
faction, which was further partitioned between water and chloroform. The
chloroform phase was evaporated and suspended in a minimum volume of
chloroform. The addition of acetone overnight at 4C led to formation of
a precipitate, which was centrifuged (3000 g at 4C for 15 min) to generate
an ‘‘acetone-soluble’’ phase and an ‘‘acetone-insoluble’’ phase. The
‘‘acetone-insoluble’’ phase was applied to a QMA-Spherosil M (BioSepra
SA, Villeneuve-la-Garonne, France) column eluted successively with chloro-
form, chloroform/methanol (1:1, v/v), methanol to elute neutral compounds
and then with chloroform/methanol (1/2, v/v) containing 0.1 M ammonium
acetate to elute negatively charged compounds. This last fraction corresponds
to the ‘‘PIM2-enriched fraction.’’
Z5B71 T cells are CD4+ and express only the TCRaV25S1J52 and
TCRbV9S1J2S5 TCR chains, confirming their clonality.
Lipidic Fractions from Several Actinomycetes
Different lipidic fractions were prepared (as described above) from several
actinomycetes species and tested with Z5B71 T cell clone. Lipidic fractions
from the following bacteria were tested: M. smegmatis, M. tuberculosis
H37Ra, M. fortuitum, M. xenopi, N. asteroides, C. glutamicum, the ‘‘acetone-
soluble’’ phase from M. smegmatis, M. tuberculosis H37Rv, M. gastri, M. kan-
sasii, M. marinum, and M. bovis BCG. The ‘‘acetone-insoluble’’ lipids from, 82–92, January 30, 2009 ª2009 Elsevier Ltd All rights reserved 89
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were also tested.
Purification of the GroMM from M. bovis BCG
The acetone-insoluble fraction from M. bovis BCG, obtained as described
above, was subjected to methanol precipitation giving ‘‘methanol soluble’’
and ‘‘methanol insoluble’’ fractions. The methanol-insoluble fraction
(150 mg) was fractionated on a silica acid column (1.3 3 23 cm) eluted with
7 3 175 ml chloroform (fractions 1–7), 8x200 ml of chloroform - methanol
(95:5, v/v) (fractions 8-15), 9x225 ml of chloroform - methanol (9:1, v/v) (frac-
tions 16-24), 7 3 175 ml chloroform-methanol (85:15, v/v) (fractions 25–31),
and 7 3 175 ml chloroform-methanol (7:3, v/v) (fractions 32–38). Fractions 5
to 8 were found to contain GroMM and were pooled.
Purifications were checked by TLC on aluminum-backed silica gel plates
(Alugram Sil G; Macherey-Nagel) using as migration solvent chloroform/meth-
anol (95:5, v/v). Anthrone (9,10-dihydro-9-oxo-anthracene; Sigma) at 0.2%
dissolved in H2SO4 at 85% was used to detect glycolipids.
GroMM Acetylation
Peracetylation was performed on 200 mg GroMM, which was dissolved in ace-
tic anhydride/anhydrous pyridine (1:1, v/v) and heated at 80C for 30 min. The
reaction mixture was dried under a stream of nitrogen and dissolved in chloro-
form for MALDI-TOF MS analysis. For selective acetylation of GroMM hydroxyl
functions, 16 ml acetic acid was added to 10 mg GroMM dissolved in 150 ml
pyridine and kept for 3 hr at 0C. Mono- and diacetylated GroMM were ex-
tracted by CHCl3 and purified on silica column eluted successively by CHCl3
and CHCl3/CH3OH 95/5 (v/v). The number of acetyl substituents and their loca-
tion on GroMM were determined by MALDI-TOF MS and NMR analysis.
GroMM Saponification
A total of 800 ml methoxyethanol/KOH 20% (7:1, v/v) was added to 500 mg
GroMM. The mixture was then heated at 100C for 3 h. After cooling and acid-
ification by aqueous sulfuric acid at pH 3.0, mycolic acids were extracted three
times by diethyl ether (v/v). Ether phases were pooled, washed five times with
water, and dried under a stream of nitrogen. Mycolic acids were redissolved in
100 ml chloroform for MALDI-TOF MS analysis.
GroMM Synthesis
Reactions were performed under argon in anhydrous solvents.
(S)-1-O-(4-Methylbenzene sulfonyl)-2,3-O,O-isopropylidene-
glycerol
p-Toluene sulfonyl chloride (0.3 g, 1.57 mmol) was added at 0C to (R)-isopro-
pylidene-glycerol (230 mg, 1.74 mmol) dissolved in anhydrous pyridine
(0.8 ml). After 24 h at room temperature, diethyl ether was added to the reac-
tion mixture and the organic phase was washed sequentially with cold, 1 M hy-
drochloric acid, water, saturated sodium bicarbonate solution, and water. The
ether extract was dried on magnesium sulfate and concentrated. Chromatog-
raphy on silica gel (elution with petroleum ether/ethyl acetate 4/1, v/v) gave the
product (around 100 mg, 0.35 mmol). In the same manner, (R)-1-O-(4 methyl-
benzene sulfonyl)-2,3-O,O-isopropylidene-glycerol was obtained from (S)-
isopropylidene-glycerol.
Potassium Mycolates
Mycolic acids (gift of Dr. M.A. Lane´elle, IPBS, Toulouse) were released from
M. tuberculosis H37Rv cells as described previously (Laval et al., 2001). Potas-
sium mycolates were obtained by two successive washings of mycolic acids
dissolved in chloroform with 10 mM hydrochloric acid and 5 M potassium
hydroxide. After extraction with chloroform, potassium mycolates were dried
on magnesium sulfate and concentrated.
(S)-1-O-Mycoloyl-2,3-O,O-isopropylidene-glycerol
Potassium mycolates (8 mg,6 mmol) were added to (S)-1-O-(4-methylbenze-
nesulfonyl)-2,3-O,O-isopropylidene-glycerol (2 mg, 7 mmol) in anhydrous di-
methylformamide (0.150 ml) and stirred for 3 days at 135C. The reaction
mixture was acidified by 1 M hydrochloric acid and extracted by diethyl ether.
Ether extract was then washed with water, dried on magnesium sulfate, and
concentrated. Chromatography on silica gel (elution with petroleum ether/di-
ethyl ether 5/1, v/v) gave the product (around 4 mg, 2.9 mmol). In the same
way, (R)-1-O-mycoloyl-2,3-O,O-isopropylidene-glycerol was obtained from
(R)-1-O-(4 methylbenzene sulfonyl)-2,3-O,O-isopropylidene-glycerol.90 Chemistry & Biology 16, 82–92, January 30, 2009 ª2009 Elsevier(S)-1-O-Mycoloyl-glycerol (GroMM)
A total of 100 ml concentrated hydrochloric acid (d = 1.017) was added to (S)-1-
O-mycoloyl-2,3-O,O-isopropylidene-glycerol (4 mg, 2.9 mmol) dissolved in
diethyl ether (0.1 ml). After 10 min of stirring at room temperature, water was
added to the reaction mixture and the product (3 mg, 2.3 mmol) was extracted
with diethyl ether. The ether extract was dried on magnesium sulfate and
concentrated. Supplemental purification was not necessary. (R)-1-O-myco-
loyl-glycerol was also obtained using (R)-1-O-mycoloyl-2,3-O,O-isopropyli-
dene-glycerol.
MALDI-TOF MS
MALDI-TOF MS analysis was performed on a 4700 Proteomics Analyzer (with
Tof-Tof Optics, Applied Biosystems) using the reflectron mode. Ionization was
effected by irradiation with pulsed ultraviolet irradiation (UV) light (355 nm) from
an Nd:YAG laser. GroMM samples were analyzed by the instrument operating
at 20 kV in the positive ion mode using an extraction delay time set at 20 ns.
Typically, spectra from 100 to 250 laser shots were summed to obtain the final
spectrum. The HABA (2-[4-hydroxy-phenylazo]-benzoic acid) matrix (Sigma-
Aldrich) was used at a concentration of 10 mg/ml in ethanol/water (1:1, v/v).
Then, 0.5 ml sample solution and 0.5 ml matrix solution were deposited on the
target, mixed with a micropipette, and dried under a gentle stream of warm
air. The measurements were externally calibrated at two points with mycobac-
terial PIM.
NMR Analysis
NMR spectra were recorded with an Avance DMX500 spectrometer (Bruker)
equipped with an Origin 200 SGI using Xwinnmx 2.6. GroMM was dissolved
in CDCl3-CD3OD, (9:1, v/v) and analyzed in 200 3 5 mm 535-PP NMR tubes
at 298 K. Proton chemical shifts are expressed in parts per million downfield
from the signal of the chloroform (dH/TMS 7.27). All details concerning cor-
relation spectroscopy and homonuclear Hartmann-Hahn spectroscopy
sequences used and experimental procedures were as previously described
(Gilleron et al., 2003).
Recognition of GroMM by Lymphocytes from Tuberculosis Patients
and Healthy Donors
PBMCs were purified from blood of healthy donors and tuberculosis patients
after informed consent was given. All patients included in this study had
culture-proven pulmonary tuberculosis and were undergoing treatment with
antituberculosis drugs for 2 to 8 weeks at the time of blood donation. PBMCs
(105/well) were cultured with autologous DCs (23 104/well) in the presence or
absence of 10 mg/ml natural GroMM. After 6 days supernatants were collected
and tested for the presence of IFN-g by sandwich ELISA. PBMCs were kept at
37C in supplemented RPMI 1640 medium (see above) during the 2 days of
autologous monocytes differentiation to DCs. In parallel, PBMCs were stimu-
lated with 10 mg/ml PPD (Chiron) and recombinant ESAT6 (Lionex). Healthy
donors that responded by releasing at least 250 pg/ml IFN-g in response to
PPD were scored as BCG immunized. Donors that responded to both antigens
were considered as latently M. tuberculosis infected. Those that did not
respond to PPD were scored as PPD negative.
CD1 restriction was tested using a cocktail of CD1a-, CD1b-, and CD1c-
blocking antibodies (10H3, BCD1b3.1 and F10 at 10 mg/ml each, resulting in
a final concentration of 30 mg/ml) added 30 min before GroMM to prevent
CD1 presentation. For individual experiments, the three antibodies were
tested separately at a final concentration of 20 mg/ml. An isotype matched anti-
body served as control.
Molecular Modeling
CD1b in complex with GroMM was obtained from GlcMM by replacing the
glucose moiety in the glycolipid head of the molecule by glycerol. The starting
point for this work was the crystal structure of the CD1b-GlcMM complex
(Batuwangala et al., 2004). The Builder and Biopolymer modules of InsightII
(BIOSYM/MSI, San Diego) were used to replace the glucose moiety by glyc-
erol. The bonds and partial charges were corrected and adjusted to the
CVFF force field. In order to position the new fragment optimally with respect
to the neighboring residues, we minimized the energy of the molecule with the
Discover module, following the standard simulated annealing protocol. During
the procedure, only the glycerol atoms were allowed to move, along with theLtd All rights reserved
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GroMM Stimulates CD1b-Restricted CD4+ T Cellsside chains of Phe75 and Arg79, the closest spatial neighbors. Molecular
dynamics was simulated during 20 ps with the time step of 1 fs, with temper-
ature initially raised to 1000 K and gradually lowered to 300 K. The minimization
was performed with the Conjugate Gradient algorithm, and was terminated
upon reaching the threshold value for the root-mean-square gradients of
0.001 kcal/mol. To be able to compare the results directly with the original
complex, we subjected the CD1b-GlcMM complex to the identical procedure.
SUPPLEMENTAL DATA
The Supplemental Data include five figures and can be found with this arti-
cle online at http://www.cell.com/chemistry-biology/supplemental/S1074-
5521(08)00455-9.
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